Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis

Nature

Volumn 461, Issue 7268, 2009, Pages 1287-1291

  Spite, Matthew ^a   Norling, Lucy V ^a,b   Summers, Lisa ^a   Yang, Rong ^a   Cooper, Dianne ^b   Petasis, Nicos A ^c   Flower, Roderick J ^b   Perretti, Mauro ^b   Serhan, Charles N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; NITRIC OXIDE; RESOLVIN D2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

BLOOD; ENZYME ACTIVITY; EXUDATION; GENE EXPRESSION; HORMONE; LIPID; MICROORGANISM; NITRIC OXIDE; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CYTOKINE PRODUCTION; DRUG MECHANISM; GENE LOCUS; IN VIVO STUDY; INFLAMMATION; LEUKOCYTE; LEUKOCYTE ADHERENCE; MACROPHAGE; MALE; MONONUCLEAR CELL; MOUSE; NEUTROPHIL; NONHUMAN; PERITONITIS; PHAGOCYTOSIS; PRIORITY JOURNAL; SEPSIS; STEREOCHEMISTRY; SURVIVAL;

ANIMALS; DOCOSAHEXAENOIC ACIDS; ENDOTHELIAL CELLS; ESCHERICHIA COLI; HUMANS; INFLAMMATION; LEUKOCYTES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE; PERITONEAL CAVITY; PERITONITIS; PHAGOCYTOSIS; REACTIVE OXYGEN SPECIES; SEPSIS;

BACTERIA (MICROORGANISMS); MUS;

EID: 70350678971     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature08541     Document Type: Article

References (32)

1. Gilroy, D. W., Lawrence, T., Perretti, M. & Rossi, A. G. Inflammatory resolution: new opportunities for drug discovery. Nature Rev. Drug Discov. 3, 401-416 (2004).
2. Serhan, C. N., Chiang, N. & Van Dyke, T. E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nature Rev. Immunol. 8, 349-361 (2008).
3. Serhan, C. N. et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025-1037 (2002).
4. Weber, C., Zernecke, A. & Libby, P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nature Rev. Immunol. 8, 802-815 (2008).
5. Hotchkiss, R. S. & Karl, I. E. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348, 138-150 (2003).
6. Shimizu, T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 49, 123-150 (2009).
7. Hong, S., Gronert, K., Devchand, P. R., Moussignac, R. L. & Serhan, C. N. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J. Biol. Chem. 278, 14677-14687 (2003).
8. Shimizu, T., Radmark, O. & Samuelsson, B. Enzyme with dual lipoxygenase activities catalyzes leukotriene A4 synthesis from arachidonic acid. Proc. Natl Acad. Sci. USA 81, 689-693 (1984).
9. Rodriguez, A. R. & Spur, B. W. First total synthesis of 7(S),16(R),17(S)-Resolvin D2, a potent anti-inflammatory lipid mediator. Tetrahedr. Lett. 45, 8717-8720 (2004).
10. Prescott, S. M., Zimmerman, G. A., Stafforini, D. M. & McIntyre, T. M. Platelet-activating factor and related lipid mediators. Annu. Rev. Biochem. 69, 419-445 (2000).
11. Cooper, D., Norling, L. V. & Perretti, M. Novel insights into the inhibitory effects of Galectin-1 on neutrophil recruitment under flow. J. Leukoc. Biol. 83, 1459-1466 (2008).
12. Rittirsch, D. et al. Functional roles for C5a receptors in sepsis. Nature Med. 14, 551-557 (2008).
13. Kubes, P., Suzuki, M. & Granger, D. N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl Acad. Sci. USA 88, 4651-4655 (1991).
14. Moncada, S. & Higgs, E. A. The discovery of nitric oxide and its role in vascular biology. Br. J. Pharmacol. 147 (Suppl. 1), S193-S201 (2006).
15. Bucci, M. et al. Endothelial nitric oxide synthase activation is critical for vascular leakage during acute inflammation in vivo. Proc. Natl Acad. Sci. USA 102, 904-908 (2005).
16. Paul-Clark, M. J., Van Cao, T., Moradi-Bidhendi, N., Cooper, D. & Gilroy, D. W. 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J. Exp. Med. 200, 69-78 (2004).
17. Rittirsch, D., Huber-Lang, M. S., Flierl, M. A. & Ward, P. A. Immunodesign of experimental sepsis by cecal ligation and puncture. Nature Protocols 4, 31-36 (2009).
18. Buras, J. A., Holzmann, B. & Sitkovsky, M. Animal models of sepsis: setting the stage. Nature Rev. Drug Discov. 4, 854-865 (2005).
19. Singer, P. et al. Anti-inflammatory properties of omega-3 fatty acids in critical illness: novel mechanisms and an integrative perspective. Intensive Care Med. 34, 1580-1592 (2008).
20. Farolan, L. R., Goto, M., Myers, T. F., Anderson, C. L. & Zeller, W. P. Perinatal nutrition enriched with omega-3 polyunsaturated fatty acids attenuates endotoxic shock in newborn rats. Shock 6, 263-266 (1996).
21. Pluess, T. T. et al. Intravenous fish oil blunts the physiological response to endotoxin in healthy subjects. Intensive Care Med. 33, 789-797 (2007).
22. Haworth, R. et al. The macrophage scavenger receptor type A is expressed by activated macrophages and protects the host against lethal endotoxic shock. J. Exp. Med. 186, 1431-1439 (1997).
23. Litvak, V. et al. Function of C/EBPdelta in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals. Nature Immunol. 10, 437-443 (2009).
24. Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nature Rev. Immunol. 8, 958-969 (2008).
25. Flierl, M. A. et al. Adverse functions of IL-17A in experimental sepsis. FASEB J. 22, 2198-2205 (2008).
26. Souza, D. G. et al. The required role of endogenously produced lipoxin A4 and annexin-1 for the production of IL-10 and inflammatory hyporesponsiveness in mice. J. Immunol. 179, 8533-8543 (2007).
27. Osuchowski, M. F., Welch, K., Siddiqui, J. & Remick, D. G. Circulating cytokine/ inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J. Immunol. 177, 1967-1974 (2006).
28. Huang, X. et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc. Natl Acad. Sci. USA 106, 6303-6308 (2009).
29. Dombrovskiy, V. Y., Martin, A. A., Sunderram, J. & Paz, H. L. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit. Care Med. 35, 1244-1250 (2007).
30. Chatterjee, B. E. et al. Annexin 1-deficient neutrophils exhibit enhanced transmigration in vivo and increased responsiveness in vitro. J. Leukoc. Biol. 78, 639-646 (2005).
31. Serhan, C. N., Lu, Y., Hong, S. & Yang, R. Mediator lipidomics: search algorithms for eicosanoids, resolvins, and protectins. Methods Enzymol. 432, 275-317 (2007).
32. Takano, T., Clish, C. B., Gronert, K., Petasis, N. & Serhan, C. N. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J. Clin. Invest. 101, 819-826 (1998).